Cantabio Pharmaceuticals Awarded Grant From The Michael J. Fox Foundation to Develop Novel Small-Molecule Aggregation Inhibitors of the Tau Protein for the Treatment of Parkinson’s Disease
Summary
Grant enables the further development of Cantabios novel small-molecule tau protein aggregation inhibitors, which have high therapeutic potential in both disease-modifying and preventive contexts for the treatment of Parkinsons and Alzheimers disease.PALO ALTO, CA / ACCESSWIRE / January 5, 2022 / Cantabio Pharmaceuticals, Inc. ("Cantabio" or the "Company"), a preclinical stage pharmaceutical company developing disease-modifying therapeutics for Alzheimers disease (AD), Parkinsons disease (PD) and Type II diabetes, today announced that The Michael J. The premise of this project is that small-molecule drug candidates that reduce the aggregation of tau will diminish neurodegeneration and slow the progression of PD and AD.Cantabio has been developing small molecules (pharmacological chaperones) that bind to the monomeric form of tau and thereby reduce its aggregation through stabilizing and promoting its functional monomeric native state. We are proud to support Cantabios approach targeting this pathology and building potential to slow or prevent progression for millions of people. The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinsons disease. It has funded $1.5B in research programs to date.Cantabio is focused on bringing novel, disease modifying, first-in-class drug candidates into clinical trials through the discovery and development of innovative pharmacological chaperone and protein delivery-based therapeutics for the treatment of Alzheimers (AD), Parkinsons (PD) and Type II Diabetes.